Work and Productivity Loss in the Rizatriptan Multiple Attack Study

The objective of this study was to measure the self-reported effect of acute migraine and its treatment on paid work and productivity loss. Patients self-administered a questionnaire in which the impact of a recent migraine on paid work and productivity activities was assessed. We included the quest...

Full description

Saved in:
Bibliographic Details
Published in:Cephalalgia 2000-11, Vol.20 (9), p.830-834
Main Authors: Dasbach, EJ, Carides, GW, Gerth, WC, Santanello, NC, Pigeon, JG, Kramer, MS
Format: Article
Language:English
Subjects:
Absenteeism
Adult
cost
Efficiency - drug effects
Female
Humans
Male
Middle Aged
migraine
Migraine Disorders - drug therapy
Migraine Disorders - physiopathology
Multicenter Studies as Topic
productivity
Randomized Controlled Trials as Topic
Rizatriptan
Serotonin Receptor Agonists - therapeutic use
Surveys and Questionnaires
Triazoles - therapeutic use
Tryptamines
Work
work loss
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to measure the self-reported effect of acute migraine and its treatment on paid work and productivity loss. Patients self-administered a questionnaire in which the impact of a recent migraine on paid work and productivity activities was assessed. We included the questionnaire in a randomized, double-blind, placebo-controlled, crossover, out-patient study designed to examine the safety and efficacy of rizatriptan (5-HT1B/1D receptor agonist) 10 mg p.o. in patients treating four separate migraine attacks. A total of 407 patients, aged 18–65 years, suffering from moderate to severe migrainous headaches was studied. Patients receiving rizatriptan compared with placebo reported 0.7 fewer hours (P < 0.01) of paid worked missed due to absenteeism, 0.4 fewer hours (P < 0.05) of productive time lost on the job, and 1.1 fewer total hours (P < 0.01) of work loss per migraine attack. Rizatriptan compared with placebo significantly reduced migraine-related work loss associated with absenteeism and decreased effectiveness on the job.
ISSN:0333-1024
1468-2982
DOI:10.1046/j.1468-2982.2000.00126.x